About ARTHEx
ARTHEx is a company based in Valencia (Spain) founded in 2018. ARTHEx has raised $93.61 million across 9 funding rounds from investors including European Investment Bank, EIT Health and Bpifrance. ARTHEx offers products and services including Anti-miR Therapy. ARTHEx operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
- Headquarter Valencia, Spain
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$93.61 M (USD)
in 9 rounds
-
Latest Funding Round
$40.64 M (USD), Series B
Sep 17, 2025
-
Investors
European Investment Bank
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ARTHEx
ARTHEx offers a comprehensive portfolio of products and services, including Anti-miR Therapy.
Investigational drug targeting microRNAs for Myotonic Dystrophy treatment
People of ARTHEx
Unlock access to complete
Unlock access to complete
Funding Insights of ARTHEx
ARTHEx has successfully raised a total of $93.61M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $40.64 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ARTHEx
ARTHEx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, EIT Health and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Columbus Venture Partners is focused on biotechnology investment funds.
|
Locked | Locked | Locked | |
|
AdBio Partners is engaged in early-stage life sciences investments.
|
Locked | Locked | Locked | |
|
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies.
|
Locked | Locked | Locked |
Investor details for ARTHEx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ARTHEx
Investment portfolio details for ARTHEx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ARTHEx
Detailed financials for ARTHEx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arthex Comparisons
Peer comparison for ARTHEx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ARTHEx
ARTHEx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
Detailed competitors of ARTHEx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arthex
Complete news archive for ARTHEx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ARTHEx
ARTHEx was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ARTHEx is headquartered in Valencia, Spain. It is registered at Valencia, Valencian Community, Spain.
ARTHEx is a funded company, having raised a total of $93.61M across 9 funding rounds to date.
ARTHEx was founded in 2018 in Valencia, Spain, within the biotechnology sector. Oligonucleotide-based treatments for neuromuscular disorders are developed, with emphasis on Myotonic Dystrophy. The lead candidate is engineered to block miRNAs that suppress MBNL12 expression, addressing the functional loss of MBNL proteins. Research and development activities are conducted to advance these therapies toward clinical applications.
ARTHEx's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
ARTHEx offers Anti-miR Therapy.
ARTHEx has 11 investors. Key investors include European Investment Bank, EIT Health, Bpifrance, European Union, and CDTI.